Karyopharm Therapeutics, Inc. (KPTI)
8.06
+0.08
(+1.00%)
USD |
NASDAQ |
May 21, 16:00
8.06
0.00 (0.00%)
After-Hours: 19:59
Karyopharm Therapeutics Research and Development Expense (TTM) : 124.57M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Gilead Sciences, Inc. | 5.703B |
| Catalyst Pharmaceuticals, Inc. | 11.48M |
| Oncolytics Biotech, Inc. | 10.77M |
| Altimmune, Inc. | 66.69M |
| Cellectar Biosciences, Inc. | 11.08M |